Ekso Bionics (NASDAQ:EKSO – Get Free Report) and iRadimed (NASDAQ:IRMD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.
Profitability
This table compares Ekso Bionics and iRadimed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ekso Bionics | -91.37% | -110.52% | -50.71% |
| iRadimed | 26.82% | 23.83% | 20.83% |
Institutional & Insider Ownership
6.4% of Ekso Bionics shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 6.1% of Ekso Bionics shares are owned by company insiders. Comparatively, 36.8% of iRadimed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ekso Bionics | $12.80 million | 2.68 | -$11.69 million | ($5.14) | -1.87 |
| iRadimed | $83.81 million | 14.26 | $22.48 million | $1.75 | 53.45 |
iRadimed has higher revenue and earnings than Ekso Bionics. Ekso Bionics is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Ekso Bionics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Ekso Bionics and iRadimed, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ekso Bionics | 1 | 1 | 0 | 0 | 1.50 |
| iRadimed | 0 | 1 | 3 | 1 | 3.00 |
Ekso Bionics presently has a consensus price target of $6.00, suggesting a potential downside of 37.69%. iRadimed has a consensus price target of $120.00, suggesting a potential upside of 28.29%. Given iRadimed’s stronger consensus rating and higher probable upside, analysts clearly believe iRadimed is more favorable than Ekso Bionics.
Summary
iRadimed beats Ekso Bionics on 15 of the 15 factors compared between the two stocks.
About Ekso Bionics
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
